OncoCyte Corp logo

OncoCyte Corp

$ 0.40 +0.0101 (+2.59%) 02:38 PM EST
P/E:
At Loss
P/B:
0.62
Market Cap:
$ 47.47M
Enterprise V:
$ 17.57M
Volume:
266.18K
Avg Vol (2M):
353.71K
Also Trade In:
Volume:
266.18K
Market Cap $:
47.47M
PE Ratio:
At Loss
Avg Vol (2-Month):
353.71K
Enterprise Value $:
17.57M
PB Ratio:
0.62
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for OCX ( OncoCyte Corp ) from 2015 to Feb 06 2023. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. OncoCyte stock (OCX) PE ratio as of Feb 06 2023 is 0. More Details

OncoCyte Corp (OCX) PE Ratio (TTM) Chart

To

OncoCyte Corp (OCX) PE Ratio (TTM) Historical Data

Total 1224
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
OncoCyte PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2023-02-06 At Loss 2022-11-30 At Loss
2023-02-03 At Loss 2022-11-29 At Loss
2023-02-02 At Loss 2022-11-28 At Loss
2023-02-01 At Loss 2022-11-25 At Loss
2023-01-31 At Loss 2022-11-23 At Loss
2023-01-30 At Loss 2022-11-22 At Loss
2023-01-27 At Loss 2022-11-21 At Loss
2023-01-26 At Loss 2022-11-18 At Loss
2023-01-25 At Loss 2022-11-17 At Loss
2023-01-24 At Loss 2022-11-16 At Loss
2023-01-23 At Loss 2022-11-15 At Loss
2023-01-20 At Loss 2022-11-14 At Loss
2023-01-19 At Loss 2022-11-11 At Loss
2023-01-18 At Loss 2022-11-10 At Loss
2023-01-17 At Loss 2022-11-09 At Loss
2023-01-13 At Loss 2022-11-08 At Loss
2023-01-12 At Loss 2022-11-07 At Loss
2023-01-11 At Loss 2022-11-04 At Loss
2023-01-10 At Loss 2022-11-03 At Loss
2023-01-09 At Loss 2022-11-02 At Loss
2023-01-06 At Loss 2022-11-01 At Loss
2023-01-05 At Loss 2022-10-31 At Loss
2023-01-04 At Loss 2022-10-28 At Loss
2023-01-03 At Loss 2022-10-27 At Loss
2022-12-30 At Loss 2022-10-26 At Loss
2022-12-29 At Loss 2022-10-25 At Loss
2022-12-28 At Loss 2022-10-24 At Loss
2022-12-27 At Loss 2022-10-21 At Loss
2022-12-23 At Loss 2022-10-20 At Loss
2022-12-22 At Loss 2022-10-19 At Loss
2022-12-21 At Loss 2022-10-18 At Loss
2022-12-20 At Loss 2022-10-17 At Loss
2022-12-19 At Loss 2022-10-14 At Loss
2022-12-16 At Loss 2022-10-13 At Loss
2022-12-15 At Loss 2022-10-12 At Loss
2022-12-14 At Loss 2022-10-11 At Loss
2022-12-13 At Loss 2022-10-10 At Loss
2022-12-12 At Loss 2022-10-07 At Loss
2022-12-09 At Loss 2022-10-06 At Loss
2022-12-08 At Loss 2022-10-05 At Loss
2022-12-07 At Loss 2022-10-04 At Loss
2022-12-06 At Loss 2022-10-03 At Loss
2022-12-05 At Loss 2022-09-30 At Loss
2022-12-02 At Loss 2022-09-29 At Loss
2022-12-01 At Loss 2022-09-28 At Loss

OncoCyte Corp (OCX) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.